USING IMMUNOMODULATING DRUG GALAVIT IN TREATMENT OF INFLUENZA

Abstract

Aim – to evaluate the effectiveness of immunomodulating drug Galavit in patients with uncomplicated influenza. Materials and methods. Non-randomized single-center comparative study was performed. Patients with influenza (male, average age – 25,1 ± 1,3 years, n = 45) were divided into 2 groups. Study group (n = 20) from the time of admission received the drug Galavit in addition to symptomatic and detoxification therapy. Patients in the control group (n = 25) received only symptomatic and detoxication therapy. The criterion of effectiveness of the preparation was positive dynamics of clinical symptoms and the results of clinical blood. Results. For the 2nd day of the disease 15 % of patients of the group returned to normal body temperature (in the control group, none of the patients had normal body temperature to the 2nd day of illness). By the 5th day of observation, 95 % of the study group patients showed normalization of body temperature (in the control group – 84 % of patients). Catarrhal symptoms resolved faster in patients of the main group than in patients of control group. Patients treated with Galavit observed normal levels of white blood cells and ESR by the moment of hospital discharge, in the control group leukocytosis and increased ESR remained. Conclusion. Galavit drug reduces the duration of catarrhal and intoxication syndrome in patients with influenza, effect positively on hematological parameters: helps reduce the number of white blood cells, stab shift, normalization of ESR.

Keywords

• influenza
• uncomplicated forms
• inductors of interferon treatment